Department of Physics, Chemistry and Biology, Linköping University, Linköping, Sweden.
Wallenberg Centre for Molecular Medicine (WCMM), Linköping, Sweden.
Expert Rev Mol Diagn. 2022 Mar;22(3):265-294. doi: 10.1080/14737159.2022.2049249. Epub 2022 Mar 16.
In the increasingly challenging field of clinical microbiology, diagnosis is a cornerstone whose accuracy and timing are crucial for the successful management, therapy, and outcome of infectious diseases. Currently employed biomarkers of infectious diseases define the scope and limitations of diagnostic techniques. As such, expanding the biomarker catalog is crucial to address unmet needs and bring about novel diagnostic functionalities and applications.
This review describes the extracellular nucleases of 15 relevant bacterial pathogens and discusses the potential use of nuclease activity as a diagnostic biomarker. Articles were searched for in PubMed using the terms: 'nuclease,' 'bacteria,' 'nuclease activity' or 'biomarker.' For overview sections, original and review articles between 2000 and 2019 were searched for using the terms: 'infections,' 'diagnosis,' 'bacterial,' 'burden,' 'challenges.' Informative articles were selected.
Using the catalytic activity of nucleases offers new possibilities compared to established biomarkers. Nucleic acid activatable reporters in combination with different transduction platforms and delivery methods can be used to detect disease-associated nuclease activity patterns and for prognostic and diagnostic applications. Even when these patterns are not obvious or of unknown etiology, screening platforms could be used to identify new disease reporters.
在日益具有挑战性的临床微生物学领域,诊断是一个基石,其准确性和及时性对于传染病的成功管理、治疗和结果至关重要。目前用于诊断传染病的生物标志物定义了诊断技术的范围和局限性。因此,扩大生物标志物目录对于满足未满足的需求以及带来新的诊断功能和应用至关重要。
本综述描述了 15 种相关细菌病原体的细胞外核酸酶,并讨论了核酸酶活性作为诊断生物标志物的潜在用途。使用术语“核酸酶”、“细菌”、“核酸酶活性”或“生物标志物”在 PubMed 中搜索文章。对于综述部分,使用术语“感染”、“诊断”、“细菌”、“负担”、“挑战”在 2000 年至 2019 年之间搜索原始和综述文章。选择了有启发性的文章。
与已建立的生物标志物相比,利用核酸酶的催化活性提供了新的可能性。核酸激活报告分子与不同的转导平台和递送方法相结合,可用于检测与疾病相关的核酸酶活性模式,用于预后和诊断应用。即使这些模式不明显或病因不明,也可以使用筛选平台来识别新的疾病报告分子。